| abstract |
The present invention provides a fusion protein including a mutant protein of human FGF21 and an Fc region of a human immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration, and protein stability, and a pharmaceutical composition including the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, and lipid metabolism improvement. |